Microbiome Therapeutics-Global Market Status and Trend Report 2016-2026

Table of Contents

Chapter 1 Overview of Microbiome Therapeutics

• 1.1 Definition of Microbiome Therapeutics in This Report
• 1.2 Commercial Types of Microbiome Therapeutics
  • 1.2.1 Upper GIT
  • 1.2.2 Lower GIT
• 1.3 Downstream Application of Microbiome Therapeutics
  • 1.3.1 C. difficile Infection (CDI)
  • 1.3.2 Inflammatory Bowel Disease (IBD)
  • 1.3.3 Orphan Drug
  • 1.3.4 Immuno-oncology
  • 1.3.5 Others
• 1.4 Development History of Microbiome Therapeutics
• 1.5 Market Status and Trend of Microbiome Therapeutics 2016-2026
  • 1.5.1 Global Microbiome Therapeutics Market Status and Trend 2016-2026
  • 1.5.2 Regional Microbiome Therapeutics Market Status and Trend 2016-2026

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Microbiome Therapeutics 2016-2021
• 2.2 Production Market of Microbiome Therapeutics by Regions
  • 2.2.1 Production Volume of Microbiome Therapeutics by Regions
  • 2.2.2 Production Value of Microbiome Therapeutics by Regions
• 2.3 Demand Market of Microbiome Therapeutics by Regions
• 2.4 Production and Demand Status of Microbiome Therapeutics by Regions
  • 2.4.1 Production and Demand Status of Microbiome Therapeutics by Regions 2016-2021
  • 2.4.2 Import and Export Status of Microbiome Therapeutics by Regions 2016-2021

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Microbiome Therapeutics by Types
• 3.2 Production Value of Microbiome Therapeutics by Types
• 3.3 Market Forecast of Microbiome Therapeutics by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Microbiome Therapeutics by Downstream Industry
• 4.2 Market Forecast of Microbiome Therapeutics by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Microbiome Therapeutics

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Microbiome Therapeutics Downstream Industry Situation and Trend Overview

Chapter 6 Microbiome Therapeutics Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Microbiome Therapeutics by Major Manufacturers
• 6.2 Production Value of Microbiome Therapeutics by Major Manufacturers
• 6.3 Basic Information of Microbiome Therapeutics by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Microbiome Therapeutics Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Microbiome Therapeutics Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Microbiome Therapeutics Major Manufacturers Introduction and Market Data

• 7.1 Seres Therapeutics
  • 7.1.1 Company profile
  • 7.1.2 Representative Microbiome Therapeutics Product
  • 7.1.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Seres Therapeutics
• 7.2 Assembly Biosciences
  • 7.2.1 Company profile
  • 7.2.2 Representative Microbiome Therapeutics Product
  • 7.2.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Assembly Biosciences
• 7.3 Synthetic Biologics
  • 7.3.1 Company profile
  • 7.3.2 Representative Microbiome Therapeutics Product
  • 7.3.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Synthetic Biologics
• 7.4 Interxon
  • 7.4.1 Company profile
  • 7.4.2 Representative Microbiome Therapeutics Product
  • 7.4.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Interxon
• 7.5 PureTech
  • 7.5.1 Company profile
  • 7.5.2 Representative Microbiome Therapeutics Product
  • 7.5.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of PureTech
• 7.6 Synlogic
  • 7.6.1 Company profile
  • 7.6.2 Representative Microbiome Therapeutics Product
  • 7.6.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Synlogic
• 7.7 Enterome BioScience
  • 7.7.1 Company profile
  • 7.7.2 Representative Microbiome Therapeutics Product
  • 7.7.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Enterome BioScience
• 7.8 4D Pharma
  • 7.8.1 Company profile
  • 7.8.2 Representative Microbiome Therapeutics Product
  • 7.8.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of 4D Pharma
• 7.9 Second Genome
  • 7.9.1 Company profile
  • 7.9.2 Representative Microbiome Therapeutics Product
  • 7.9.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Second Genome
• 7.10 AOBiome
  • 7.10.1 Company profile
  • 7.10.2 Representative Microbiome Therapeutics Product
  • 7.10.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of AOBiome
• 7.11 C3 Jian
  • 7.11.1 Company profile
  • 7.11.2 Representative Microbiome Therapeutics Product
  • 7.11.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of C3 Jian
• 7.12 Rebiotix
  • 7.12.1 Company profile
  • 7.12.2 Representative Microbiome Therapeutics Product
  • 7.12.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Rebiotix
• 7.13 MicroBiome Therapeutics LLC
  • 7.13.1 Company profile
  • 7.13.2 Representative Microbiome Therapeutics Product
  • 7.13.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of MicroBiome Therapeutics LLC
• 7.14 Metabiomics
  • 7.14.1 Company profile
  • 7.14.2 Representative Microbiome Therapeutics Product
  • 7.14.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Metabiomics
• 7.15 Ritter Pharmaceuticals
  • 7.15.1 Company profile
  • 7.15.2 Representative Microbiome Therapeutics Product
  • 7.15.3 Microbiome Therapeutics Sales, Revenue, Price and Gross Margin of Ritter Pharmaceuticals
• 7.16 Symberix
• 7.17 OpenBiome
• 7.18 Azitra
• 7.19 Symbiotix Biotherapies
• 7.20 Osel
• 7.21 Metabogen

Chapter 8 Upstream and Downstream Market Analysis of Microbiome Therapeutics

• 8.1 Industry Chain of Microbiome Therapeutics
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Microbiome Therapeutics

• 9.1 Cost Structure Analysis of Microbiome Therapeutics
• 9.2 Raw Materials Cost Analysis of Microbiome Therapeutics
• 9.3 Labor Cost Analysis of Microbiome Therapeutics
• 9.4 Manufacturing Expenses Analysis of Microbiome Therapeutics

Chapter 10 Marketing Status Analysis of Microbiome Therapeutics

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources